Anti-ARIH2/TRIAD1 antibody [EPR7671],Abcam,AB133653

Target data E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed : 16118314, PubMed : 17646546, PubMed : 19340006, PubMed : 24076655, PubMed : 33268465, PubMed : 34518685, PubMed : 38418882). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-5-RING ubiquitin ligase complex (ECS complex, also named CRL5 complex) and initiating ubiquitination of ECS substrates : associates with ECS complex and specifically mediates addition of the first ubiquitin on ECS targets (PubMed : 33268465, PubMed : 34518685, PubMed : 38418882). The initial ubiquitin is then elongated (PubMed : 33268465). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated form of the cullin-5 (CUL5) component of the ECS complex (PubMed : 24076655). Together with the ECS(ASB9) complex, catalyzes ubiquitination of CKB (PubMed : 33268465). Promotes ubiquitination of DCUN1D1 (PubMed : 30587576). Mediates 'Lys-6', 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed : 16118314, PubMed : 17646546, PubMed : 19340006). May play a role in myelopoiesis (PubMed : 19340006).. (Microbial infection) Following infection by HIV-1 virus, acts together with a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex) hijacked by the HIV-1 Vif protein, to catalyze ubiquitination and degradation of APOBEC3F and APOBEC3G. See full target information ARIH2